Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. katso kohdat 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Euroopan unioni - suomi - EMA (European Medicines Agency)

ge healthcare as - mangafodipir trinatriumia - magneettikuvaus - kontrastimediat - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. varjoaineen diagnostiikka magneettikuvaus (mri) havaitsemiseksi vaurioita maksan epäillään johtuvan metastasoitunut tauti tai hepatosellulaariset karsinoomat. lisänä mri tukea tutkimuksen polttoväli haiman vaurioita.

Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastiset aineet - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - muut dermatologiset valmisteet - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Suomi - suomi - Fimea (Suomen lääkevirasto)

bioveta a.s. - rabies-virus live - oraalisuspensio

Suomi - suomi - Fimea (Suomen lääkevirasto)

vetoquinol s.a. - tolfenamic acid - injektioneste, liuos - 80 mg/ml - tolfenaamihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

opella healthcare france sas - pentoxyverine citrate - tabletti, kalvopäällysteinen - 50 mg - pentoksiveriini

Suomi - suomi - Fimea (Suomen lääkevirasto)

pharmaq as - aeromonas salmonicida var salmonicida -bacteria, inactivated, listonella anquillarum, serotype 02a, inactivated, listonella anguillarum, serotype 01, inactivated - injektioneste, emulsio

Suomi - suomi - Fimea (Suomen lääkevirasto)

woikoski oy - air, medicinal - lääkkeellinen kaasu, puristettu - 100 % - lääkkeellinen ilma